Pharmas Pour Billions into Early-Stage Chinese Assets

Three recent deals in China's pharma partnering space have set a new precedent for early-stage investments, with Merck, Novo, and Novartis each committing at least $300 million up front for assets with little or no clinical data. These agreements signal a shift away from the focus on cancer antibodies that defined the early days of pharma partnering in China.

The deals span three disease areas and three modalities, illustrating the expanding scope of pharma's interest in Chinese partners. Each agreement has a total potential value exceeding $2 billion, demonstrating the substantial commitments being made by these pharmaceutical companies.